Efficacy News and Research

RSS
New NPS information on dextropropoxyphene: recommendations and alternatives

New NPS information on dextropropoxyphene: recommendations and alternatives

IOM report identifies options that could further improve information obtained from pediatric studies

IOM report identifies options that could further improve information obtained from pediatric studies

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer new treatment hope for MS patients

iBio receives U.S. patent for fusion-protein vaccine technology

iBio receives U.S. patent for fusion-protein vaccine technology

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec announces new easier to use injection for multiple sclerosis

Scientists to speak on cultural issues pertinent to rehabilitation research

Scientists to speak on cultural issues pertinent to rehabilitation research

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Simple and accurate device to study malaria

Simple and accurate device to study malaria

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept fourth quarter revenue decreases to $0.2 million

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter commences CD34+ stem cell phase III trial in CMI

ICON announces acquisition of PriceSpective

ICON announces acquisition of PriceSpective

DBV receives FDA Fast Track Designation for Viaskin Peanut clinical development program

DBV receives FDA Fast Track Designation for Viaskin Peanut clinical development program

Dompé enters definitive agreement to acquire Anabasis

Dompé enters definitive agreement to acquire Anabasis

BioConnections, Yissum to commercialize kits that detect MDR and XDR infections

BioConnections, Yissum to commercialize kits that detect MDR and XDR infections

ATI commences European trial of neurostimulation system for migraine

ATI commences European trial of neurostimulation system for migraine

Chronic pain patients at high-risk for comorbid substance abuse benefit from 3-week program

Chronic pain patients at high-risk for comorbid substance abuse benefit from 3-week program

News briefs from featured presentations at Cardiology 2012

News briefs from featured presentations at Cardiology 2012

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

Evolutionary forces encourage diversity in the active surfaces of venomous toxins

Evolutionary forces encourage diversity in the active surfaces of venomous toxins

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.